Table 2 Hazard ratios for incidence of hepatocellular carcinoma and mortality according to statin use
No of case (100 persons year) | Crude HR (95% CI) | Adjusted HRa (95% CI) | |
|---|---|---|---|
HCC | |||
Statin nonuser | 170 (0.3) | Reference | Reference |
Statin user | 37 (0.2) | 0.56 (0.39, 0.80) | 0.56 (0.39, 0.80) |
Liver cancer or liver-related mortality | |||
Statin nonuser | 86 (0.2) | Reference | Reference |
Statin user | 17 (0.1) | 0.57 (0.33, 0.94) | 0.59 (0.35, 0.99) |
Extrahepatic cancer-related mortality | |||
Statin nonuser | 85 (0.2) | Reference | Reference |
Statin user | 34 (0.2) | 1.13 (0.76, 1.68) | 1.12 (0.75, 1.67) |
Cardiovascular disease-related mortality | |||
Statin nonuser | 42 (0.1) | Reference | Reference |
Statin user | 14 (0.1) | 0.94 (0.51, 1.72) | 0.96 (0.52, 1.79) |
All-cause mortality | |||
Statin nonuser | 302 (0.6) | Reference | Reference |
Statin user | 101 (0.6) | 0.94 (0.75, 1.18) | 0.93 (0.78, 1.11) |